Clinical implication of metabolic syndrome in nonobese patients with antineutrophil cytoplasmic antibody-associated vasculitis [post]

Soo Bin soobinl22@naver.com, Hyeok Chan Kwon, Jung Yoon Pyo, Mi Il Kang, Jason Jungsik Song, Yong-Beom Park, Jun Yong Park, Sang-Won Lee
2020 unpublished
Objective: We investigated the prevalence of metabolic syndrome (MetS) in all or nonobese patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and compared it with age- and gender-matched controls. Also, we assessed the effect of variables at diagnosis on the risk of cardiovascular disease (CVD) in all or nonobese AAV patients. Methods: In this study, 173 AAV patients and 344 controls were included and MetS was defined by the National Cholesterol Education
more » ... ol Education Program Adults Treatment Panel III criteria. The obesity based on BMI was defined as BMI ≥ 25 kg/m 2 . The follow-up duration was defined as the period from diagnosis to the last visit or to each poor outcome occurrence. Results: The median age of AAV patients was 58.7 years and 57 patients were men. The prevalence of MetS was 50.9% in all AAV patients and 46.5% in nonobese AAV patients, which were significantly higher than 37.8% in all controls and 28.2% in nonobese controls. In the Kaplan-Meier survival analysis, Mets at diagnosis significantly reduced the cumulative CVD-free survival rate in both all and nonobese AAV patients. In the multivariable Cox hazards model analysis, CVD during follow-up was significantly associated with both BVAS (HR 1.159) and MetS at diagnosis (HR 9.036) in nonobese AAV patients. Conclusions: The prevalence of MetS at diagnosis in all or nonobese AAV patients was significantly higher than those in all or nonobese controls. Furthermore, both BVAS and MetS at diagnosis increased the risk of CVD in nonobese AAV patients.
doi:10.21203/rs.3.rs-28821/v1 fatcat:rn7bzmk2bzfbph56lqdx6uz4uu